fospropofol + propofol
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ischemic Coronary Artery Disease
Conditions
Ischemic Coronary Artery Disease, Coronary Artery Bypass Surgery
Trial Timeline
Jun 1, 2002 → Jul 1, 2003
NCT ID
NCT00209521About fospropofol + propofol
fospropofol + propofol is a phase 2 stage product being developed by Eisai for Ischemic Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00209521. Target conditions include Ischemic Coronary Artery Disease, Coronary Artery Bypass Surgery.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00209521 | Phase 2 | Completed |
Competing Products
20 competing products in Ischemic Coronary Artery Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin, Clopidogrel | Yuhan | Pre-clinical | 23 |
| DS-1040b + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| DS-1040b + Aspirin | Daiichi Sankyo | Phase 1 | 33 |
| DS1040b + Placebo | Daiichi Sankyo | Pre-clinical | 23 |
| Pharmacological intensification based on olmesartan | Daiichi Sankyo | Phase 2 | 52 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| YM872 (zonampanel), t-PA (alteplase) | Astellas Pharma | Phase 2 | 52 |
| Regadenoson | Astellas Pharma | Approved | 85 |
| ASP2246 | Astellas Pharma | Phase 1/2 | 41 |
| Gadolinium + Adenosine | Astellas Pharma | Phase 2/3 | 65 |
| XY03-EA + XY03-EA Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Redasemtide + Placebo | Shionogi | Phase 2 | 52 |
| Statin | Shionogi | Approved | 85 |
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 23 |
| SB623 Implant (2.5M) + SB623 Implant (5.0M) | Sumitomo Pharma | Phase 2 | 52 |
| Mesenchymal stem cell + Placebo | Rohto Pharmaceutical | Phase 2 | 52 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 52 |
| Balovaptan + Placebo | Roche | Phase 2 | 52 |
| Repatha | Amgen | Approved | 84 |
| GS-6615 + Placebo | Gilead Sciences | Phase 1 | 32 |